|
AAb to TAA | Positive | Total | % | Comment | Reference |
|
p53 | 10 | 30 | 33 | | [43] |
p53 | 42 | 174 | 24 | Association with shorter disease-free survival. | [30] |
p53 | 18 | 86 | 21 | No prognostic relevance for survival. | [22] |
p53 | 143 | 652 | 22 | Summary of 11 studies. Frequency of AAbs: 8.7%–92.3%. Few studies showed association with poor histological differentiation and poor survival. | [23] |
p53 | 38 | 83 | 46 | Association with higher risk for relapse. | [38] |
p53 | 21 | 113 | 19 | Correlation with tumor stage and grade. Association with worse survival. | [28] |
p53 | 28 | 113 | 25 | Serum AAbs had no prognostic relevance for survival. Ascitic AAbs were associated with adverse survival. | [24] |
p53 | 24 | 193 | 13 | No diagnostic value, even if combined with CA-125. No prognostic relevance for survival. | [45] |
p53 | 29 | 116 | 25 | Detected exclusively in type II carcinoma. | [33] |
HOXA7 | 17 | 48 | 36 | Allows no distinction between benign and malignant ovarian tumors. | [15] |
HOXB7 | 13 | 39 | 33 | Significant difference in the frequency of AAbs between ovarian carcinoma patients and healthy controls. Promising diagnostic potential. | [48] |
HSP-27 | 17 | 34 | 50 | Promising diagnostic potential. Possible association with improved survival. | [49] |
HSP-90 | 8 | 32 | 25 | Association with advanced-stage disease. Promising diagnostic potential. | [9] |
Cathepsin D | 10 | 25 | 40 | Promising diagnostic potential. | [50] |
NY-ESO-1/LAGE-1 | NR | NR | 13 | | [51] |
NY-ESO-1/LAGE-1 | 11 | 37 | 30 | No prognostic relevance for survival. Promising diagnostic potential. | [11] |
MUC1 | 306 | 668 | 46 | Correlation with a more favorable prognosis. | [52] |
GIPC-1 | 6 | 11 | 54 | Promising diagnostic potential. | [53] |
IL-8 | NR | 94 | NR | Anti-IL-8 AAb levels were elevated in ovarian carcinoma patients as compared with those of healthy controls. Promising diagnostic potential. | [54] |
Ep-CAM | 22 | 52 | 42 | Potential diagnostic value. | [55] |
S100A7 | NR | 92 | NR | Mean AAbs level was significantly higher in ovarian carcinoma patients as compared to that healthy controls. Potential diagnostic value. | [2] |
|